Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Ductal carcinoma (DCIS) is a nonobligate precursor of invasive breast cancer. Here, we sought to investigate the level of intralesion genetic heterogeneity in DCIS and the patterns of clonal architecture changes in the progression from DCIS to invasive disease.

Experimental Design: Synchronous DCIS ( = 27) and invasive ductal carcinomas of no special type (IDC-NSTs; = 26) from 25 patients, and pure DCIS ( = 7) from 7 patients were microdissected separately and subjected to high-depth whole-exome ( = 56) or massively parallel sequencing targeting ≥410 key cancer-related genes ( = 4). Somatic genetic alterations, mutational signatures, clonal composition, and phylogenetic analyses were defined using validated computational methods.

Results: DCIS revealed genetic alterations similar to those of synchronously diagnosed IDC-NSTs and of non-related IDC-NSTs from The Cancer Genome Atlas (TCGA), whereas pure DCIS lacked mutations. Clonal decomposition and phylogenetic analyses based on somatic mutations and copy number alterations revealed that the mechanisms of progression of DCIS to invasive carcinoma are diverse, and that clonal selection might have constituted the mechanism of progression from DCIS to invasive disease in 28% (7/25) of patients. DCIS displaying a pattern of clonal selection in the progression to invasive cancer harbored higher levels of intralesion genetic heterogeneity than DCIS where no clonal selection was observed.

Conclusions: Intralesion genetic heterogeneity is a common feature in DCIS synchronously diagnosed with IDC-NST. DCIS is a nonobligate precursor of IDC-NST, whose mechanisms of progression to invasive breast cancer are diverse and vary from case to case.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367727PMC
http://dx.doi.org/10.1158/1078-0432.CCR-19-2563DOI Listing

Publication Analysis

Top Keywords

dcis invasive
16
dcis
13
ductal carcinoma
12
intralesion genetic
12
genetic heterogeneity
12
progression dcis
12
clonal selection
12
invasive
8
invasive ductal
8
dcis nonobligate
8

Similar Publications

Ductal carcinoma in situ (DCIS) is a noninvasive precursor of breast cancer with a high potential for progression. Aberrant DNA methylation plays a pivotal role in early tumorigenesis, yet the regulatory mechanisms remain incompletely defined. Integrated bioinformatic analysis of methylation and transcriptomic datasets identified miR-217 as a candidate regulator of DNA methyltransferase 1 (DNMT1).

View Article and Find Full Text PDF

Background: The recently reported results from the COMET trial investigating the nonoperative management of low-risk ductal carcinoma in situ (DCIS) question the need for routine excision of atypical ductal hyperplasia (ADH). This study aimed to examine the upgrade rates of patients with ADH who met applicable COMET trial criteria.

Methods: Cases of ADH managed with surgery at our institution between 2004 and 2022 were identified, and clinical variables were extracted from the medical record.

View Article and Find Full Text PDF

Aims: Papillary carcinoma diagnosed in core needle biopsy (CNB) refers to carcinoma with papillary features but no definitive invasion, including papillary ductal carcinoma in situ (DCIS), papilloma with DCIS, encapsulated papillary carcinoma (EPC) and solid papillary carcinoma (SPC). This study assesses the upgrade rate of papillary carcinoma in CNB and supports the use of 'papillary carcinoma' as an umbrella term.

Methods: A retrospective review identified 41 CNB cases of non-invasive papillary carcinoma with subsequent excision (2011-2018).

View Article and Find Full Text PDF

Breast cancer is hallmarked by phenotypic transitions enabling abnormal cell proliferation and invasion. The stress-protective transcription factor heat shock factor 2 (HSF2) is associated with cancer, but its function in breast carcinogenesis remains poorly understood. Analysis of human breast tumor samples and mouse in vivo xenografts uncovered that HSF2 expression and activity undergo dynamic changes as a function of tumor progression.

View Article and Find Full Text PDF